Author

Anavasadat Sadr Hashemi Nejad

Hôpital Maisonneuve-RosemontORCID 0000-0002-3531-3475Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metabolomics· 1 Assay:metagenomics· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alejandro Schcolnik‐CabreraiD· 1 shared April A. N. RoseiD· 1 shared Caroline CapdevielleiD· 1 shared Donia Issa· 1 shared Frédérick A. MalletteiD· 1 shared Ivan TopisirovićiD· 1 shared Laura HuleaiD· 1 shared Martín RofféiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alejandro Schcolnik‐CabreraORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

eIF4A inhibition disrupts resistance-associated translational and metabolic programs in BRAF-mutant melanoma

Alejandro Schcolnik‐Cabrera, Meriem Takdenti, Anavasadat Sadr Hashemi Nejad, Zaynab Nouhi, Sarah St-Amand, Caroline Capdevielle, Donia Issa, Mélody Riaud, April A. N. Rose, Mireille Khacho, Frédérick A. Mallette, Martín Roffé, Tommy Alain, Ivan Topisirović, Laura Hulea

This study shows eIF4A inhibition disrupts resistance mechanisms in BRAF-mutant melanoma by targeting translational and metabolic programs, improving tumor control when combined with BRAF inhibitors.

bioRxiv · Sep 8, 2026 · PreprintCancer Biology